Literature DB >> 22432112

Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications.

Yu Sun1, Ya-Hui Chang, Hua-Fen Chen, Ying-Hwa Su, Hui-Fang Su, Chung-Yi Li.   

Abstract

OBJECTIVE: We retrospectively assessed the age- and sex-specific incidence and relative risk of Parkinson disease (PD) in Taiwan's diabetic population. RESEARCH DESIGN AND METHODS: Study cohort included 603,416 diabetic patients and 472,188 nondiabetic control subjects. Incidence rate and relative risk of PD (ICD-9-CM 332.0) were evaluated.
RESULTS: The incidence of PD was 3.59 and 2.15 per 10,000 person-years for the diabetic and control group, respectively, representing a covariate adjusted hazard ratio (HR) of 1.61 (95% CI 1.56-1.66), which was substantially reduced to 1.37 (1.32-1.41) after adjusting for medical visits. Diabetes was associated with a significantly elevated risk of PD in all sex and age stratifications except in young women, with the highest HR noted for young men aged 21-40 years (2.10 [1.01-4.42]), followed by women aged 41-60 (2.05 [1.82-2.30]) and >60 years (1.65 [1.58-1.73]).
CONCLUSIONS: Diabetes is associated with an increased risk of PD onset in a Chinese population, and the relation is stronger in women and younger patients.

Entities:  

Mesh:

Year:  2012        PMID: 22432112      PMCID: PMC3329814          DOI: 10.2337/dc11-1511

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


A few recent studies raise the possibility of increased risk of Parkinson disease (PD) among diabetic patients (1–3). However, findings reported in prior studies are not consistent (4–7). Furthermore, large-scale population-based cohort studies with detailed age and sex stratifications in Asia are rare. The current study uses a national cohort retrieved from Taiwan’s National Health Insurance (NHI) database to retrospectively investigate the age- and sex-specific associations of diabetes with the risk of incident PD.

RESEARCH DESIGN AND METHODS

Details of NHI claim data of Taiwan and methods of selection of diabetic and control groups were described previously (8,9). In brief, eligible study subjects were adult prevalent cases of diabetes with a diagnosis of diabetes (ICD-9 250 or A code 181) in 2000 (i.e., index date) who then experienced one or more diabetes diagnoses within the subsequent 12-month follow-up period. The first and last outpatient visits within 1 year had to be >30 days apart to avoid accidental inclusion of miscoded patients. The index date for subjects in the control group was the first date of enrollment to NHI. If their first date of enrollment was before 1 January 2000, the index date was set as 1 January 2000. The original study subjects consisted of 615,532 diabetic patients and 614,871 age- and sex-matched control subjects randomly selected from the registry of beneficiaries (8,9). Case subjects with a prior diagnosis of PD (ICD-9 332.xx, n = 2,977) or secondary Parkinsonism (n = 3,639) from 1 January 1997 to the index date were excluded. Case subjects aged <20 years were also excluded (n = 5,500). The same exclusion criteria were also applied to control subjects (PD, n = 1,699; secondary Parkinsonism, n = 1,398; age <20, n = 5,497). Control subjects treated for diabetes (ICD-9: 250.xx) during follow-up (i.e., 2000–2008) (n = 134,089) also were excluded to reduce the likelihood of disease misclassification. The final cohort consisted of 603,416 diabetic patients and 472,188 control subjects. We identified the first diagnoses of PD (ICD-9: 332.0) from outpatient claims or hospitalization records from 2000 to 2008 as the study end point. Only those with end point onset 1 year after the index date were retrieved to establish the temporal link between diabetes and PD. All of the study subjects were followed from the index date to occurrence of end point, withdrawal from the NHI, or 31 December 2008, whichever date came first, and the later two dates were considered as censoring observations. The age- and sex-specific incidence densities (IDs) were determined under Poisson assumption. Cox proportional hazards regression models were performed with adjustment for age, sex, geographic area, urbanization status, and comorbidities, including hypertension (ICD-9: 401–405), hyperlipidemia (ICD-9: 272), and cardiovascular disease (ICD-9: 410–414, 430–438). We also tested the interactive effects of diabetes with age or sex on risk of PD. We adjusted for geographic area to minimize the potential confounding by differential accessibility and availability of medical care (10). Adjustment for urbanization was to account for the possible urban-rural difference in prevalence of certain environmental factors, such as well-water drinking, herbicides, pesticide exposure, and neurotoxins, which have been considered as risk factors for PD (11). All statistical analyses were performed with SAS (version 9.2; SAS Institute, Cary, NC). A statistical significance was declared at a type I error of 0.05.

RESULTS

The overall ID for diabetic men and women was 3.34 and 3.82 per 10,000 patient-years, respectively, while the corresponding figures for control men and women were 2.12 and 2.18 per 10,000 patient-years. Irrespective of sex, the ID increased with age in both groups, with a dramatically high ID noted for those aged >65 years (Table 1).
Table 1

Overall and age- and sex-specific IDs and relative hazards of PD in the diabetic and control groups

Overall and age- and sex-specific IDs and relative hazards of PD in the diabetic and control groups Compared with control subjects, diabetic patients showed a significantly increased risk of PD with an adjusted hazard ratio (HR) of 1.61 (95% CI 1.56–1.66). The adjusted HR was significantly higher (β = 0.109657, P < 0.0001) in diabetic women (1.70 [1.63–1.77]) than in diabetic men (1.51 [1.44–1.57]). The interaction of diabetes with age was also statistically significant for both men (β = 0.18082, P = 0.0014) and women (β = 0.30550, P < 0.001). For men, the age-specific HR was highest in young diabetic subjects aged 21–40 years (2.10), then it declined to 1.60 and 1.49 for aged 41–60 and >60 years, respectively. The age-specific HR was lower for young women with diabetes (1.10) and was higher for middle-aged and older women with diabetes (2.05 and 1.65, respectively) (Table 1). To test the proportionality assumption of the Cox model, we performed stratified analysis according to the period of follow-up. The adjusted HR tended to be higher in earlier years (i.e., 2000–2004; 1.83 [1.75–1.91]) than in later years (i.e., 2005–2008; 1.44 [1.39–1.50]). We also calculated the HR for diabetic subjects whose dates of first-time ambulatory visit for diabetes were in 1997 or earlier, 1998–1999, or 2000 and observed an adjusted HR of 1.72 (1.66–1.77), 1.38 (1.32–1.44), and 1.25 (1.18–1.33), respectively. To examine the potential bias arising from higher ambulatory care frequency in diabetic patients, we limited control subjects to those with ≥21 ambulatory visits (the average number of ambulatory visits for nondiabetic causes in diabetes) for all causes in 2000 and noted an overall adjusted HR of 1.37 (1.32–1.41).

CONCLUSIONS

This retrospective study supports the putative link between diabetes and risk of PD (1–3). Our study provides additional information suggesting significant effect modifications by age and sex. We found a significantly higher HR of PD in diabetic women than in diabetic men. Moreover, young diabetic men aged 21–40 years or diabetic women aged 41–60 years are more vulnerable to the increased risk. The association between diabetes and PD has not been fully illustrated. It is possible that chronic inflammation and oxidative stress noted in diabetes may also lead to higher risk of PD years later (3). Besides, animal and in vitro studies show a role for insulin in the regulation of brain dopaminergic activity. Insulin dysregulation and changes in insulin action have been of concern in the pathophysiology and clinical symptoms of PD (12). Furthermore, reduced expression of certain genes in type 2 diabetes is related to impaired mitochondrial oxidative pathway, while mitochondrial dysfunction has been suggested as a pathogenesis in PD (2,13). Our finding indicates a stronger association of diabetes with early onset PD (age <60 years), which is consistent with one recent study (2). The limitation of this study is that we could not differentiate between type 1 and type 2 diabetes, despite the fact that type 1 diabetes constitutes only 1.8% of all diabetes in Taiwan (14). We limited the diabetic patients to those diagnosed after age 20 or older to further minimize this problem. In addition, because of a lack of complete information on subjects’ lifestyle and environmental or occupational exposure, our study was unable to directly adjust for the potential confounding of those variables. The HR in diabetes was substantially decreased from 1.61 to 1.37 after adjusting for frequency of ambulatory care, suggesting major confounding by medical attention, which also may explain some of the remaining risk elevation. During a 9-year study period, the diabetic patients in Taiwan experienced significantly increased risks of PD in both sexes and most ages; a stronger link between diabetes and young-onset PD deserves further investigation.
  14 in total

1.  Type 2 diabetes and the risk of Parkinson's disease.

Authors:  Gang Hu; Pekka Jousilahti; Siamak Bidel; Riitta Antikainen; Jaakko Tuomilehto
Journal:  Diabetes Care       Date:  2007-01-24       Impact factor: 19.112

2.  Accessibility assessment of the Health Care Improvement Program in rural Taiwan.

Authors:  Hsiu-Fen Tan; Hung-Fu Tseng; Chen-Kang Chang; Wender Lin; Shih-Huai Hsiao
Journal:  J Rural Health       Date:  2005       Impact factor: 4.333

3.  Obesity, diabetes, and risk of Parkinson's disease.

Authors:  Natalia Palacios; Xiang Gao; Marjorie L McCullough; Eric J Jacobs; Alpa V Patel; Tinisha Mayo; Michael A Schwarzschild; Alberto Ascherio
Journal:  Mov Disord       Date:  2011-07-07       Impact factor: 10.338

4.  Environmental and familial risk factors of Parkinsons disease: case-control study.

Authors:  Jaya Sanyal; D P Chakraborty; Biswanath Sarkar; Tapas Kumar Banerjee; Subhash Chandra Mukherjee; Bidhan Chandra Ray; V R Rao
Journal:  Can J Neurol Sci       Date:  2010-09       Impact factor: 2.104

5.  Risk of malignant neoplasms of liver and biliary tract in diabetic patients with different age and sex stratifications.

Authors:  Hua-Fen Chen; Peter Chen; Chung-Yi Li
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

6.  The current state of diabetes management in Taiwan.

Authors:  L M Chuang; S T Tsai; B Y Huang; T Y Tai
Journal:  Diabetes Res Clin Pract       Date:  2001-11       Impact factor: 5.602

Review 7.  Application of serial analysis of gene expression to the study of human genetic disease.

Authors:  Martin P Horan
Journal:  Hum Genet       Date:  2009-07-10       Impact factor: 4.132

8.  Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease.

Authors:  Kelly Claire Simon; Honglei Chen; Michael Schwarzschild; Alberto Ascherio
Journal:  Neurology       Date:  2007-08-29       Impact factor: 9.910

Review 9.  Insulin and neurodegenerative disease: shared and specific mechanisms.

Authors:  Suzanne Craft; G Stennis Watson
Journal:  Lancet Neurol       Date:  2004-03       Impact factor: 44.182

10.  Diabetes in patients with idiopathic Parkinson's disease.

Authors:  Claudia Becker; Gunnar P Brobert; Saga Johansson; Susan S Jick; Christoph R Meier
Journal:  Diabetes Care       Date:  2008-06-16       Impact factor: 19.112

View more
  63 in total

Review 1.  Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases.

Authors:  Shivani Ghaisas; Joshua Maher; Anumantha Kanthasamy
Journal:  Pharmacol Ther       Date:  2015-11-26       Impact factor: 12.310

2.  The Carnitine Palmitoyl Transferase (CPT) System and Possible Relevance for Neuropsychiatric and Neurological Conditions.

Authors:  Ashraf Virmani; Luigi Pinto; Otto Bauermann; Saf Zerelli; Andreas Diedenhofen; Zbigniew K Binienda; Syed F Ali; Feike R van der Leij
Journal:  Mol Neurobiol       Date:  2015-06-04       Impact factor: 5.590

3.  Understanding the links between cardiovascular disease and Parkinson's disease.

Authors:  Judy Potashkin; Xuemei Huang; Claudia Becker; Honglei Chen; Thomas Foltynie; Connie Marras
Journal:  Mov Disord       Date:  2019-09-04       Impact factor: 10.338

4.  "New methods of assessing autonomic disorders in Parkinson disease patients: skin-galvanic reaction".

Authors:  Justyna Dutkiewicz; Stanisław Szlufik; Andrzej Friedman
Journal:  J Neural Transm (Vienna)       Date:  2019-09-28       Impact factor: 3.575

5.  Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease.

Authors:  Samantha Molsberry; Kjetil Bjornevik; Katherine C Hughes; Zhongli Joel Zhang; Sarah Jeanfavre; Clary Clish; Brian Healy; Michael Schwarzschild; Alberto Ascherio
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

6.  GLP-1 receptor agonists for Parkinson's disease.

Authors:  Caroline A Mulvaney; Gonçalo S Duarte; Joel Handley; David Jw Evans; Suresh Menon; Richard Wyse; Hedley Ca Emsley
Journal:  Cochrane Database Syst Rev       Date:  2020-07-23

Review 7.  Diabetes Mellitus as a Risk Factor for Parkinson's Disease: a Molecular Point of View.

Authors:  Alice Biosa; Tiago F Outeiro; Luigi Bubacco; Marco Bisaglia
Journal:  Mol Neurobiol       Date:  2018-03-28       Impact factor: 5.590

Review 8.  Convergent Molecular Pathways in Type 2 Diabetes Mellitus and Parkinson's Disease: Insights into Mechanisms and Pathological Consequences.

Authors:  Sandeep Xxxx; Mir Hilal Ahmad; Linchi Rani; Amal Chandra Mondal
Journal:  Mol Neurobiol       Date:  2022-05-16       Impact factor: 5.590

Review 9.  Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Authors:  Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

10.  Combatting Nitrosative Stress and Inflammation with Novel Substituted Triazinoindole Inhibitors of Aldose Reductase in PC12 Cells Exposed to 6-Hydroxydopamine Plus High Glucose.

Authors:  Zubeyir Elmazoglu; Marta Soltesova Prnova; Abel Santamaria; Milan Stefek; Cimen Karasu
Journal:  Neurotox Res       Date:  2020-11-04       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.